Biotech Co. Finds Massive Physiological Screening Breakthrough

1. MindBio Therapeutics Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000. 
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of MindBio Therapeutics Corp.
3. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

1. Disclosure for the quote from the Stewart Thomson article published on April 1, 2026

1. For the quoted article (published on April 1, 2026), MindBio Therapeutics Corp. has paid Street Smart, an affiliate of Streetwise Reports, US$3,500.
2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts.  The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

For additional disclosures, please click here.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

On April 29, 2026, MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) announced patent application filings for its first-of-its-kind AI intoxication detection technology.

MindBio Therapeutics is a Canadian biotech company leveraging AI technology to detect impairment from drugs or alcohol through voice analysis. The company is developing software that could help reduce intoxication-related accidents in both corporate and personal settings. Its proprietary technology analyzes over 140 vocal markers, sifting through parameters like spectral entropy, jitter, and shimmer, and speech rate variability.

The company hopes to help create ". . . a world where voice-based biomarkers are a standard component of healthcare — enabling continuous, passive health monitoring that catches problems early and improves outcomes for everyone, everywhere."

MindBio's personal-use app, Booze AI, is described as "the world's first voice-activated AI-powered blood alcohol test" and is deployed via smartphone. The app is now live and available to the public. The company aims to promote social responsibility, personal awareness, and harm prevention among individual users.

In a move toward corporate usage, MindBio has focused its attention on commercial applications and is currently building Edge-AI kiosks to implement non-invasive intoxication screenings at large mining sites.

The company's CEO, Justin Hanka, said, “The digital health diagnostics market represents a significant opportunity for MindBio to leverage its Voice AI diagnostics technology with a first mover commercialization advantage in drug and alcohol intoxication detection.”

The company describes its vision as developing ". . . A world where voice-based biomarkers are a standard component of healthcare—enabling continuous, passive health monitoring that catches problems early and improves outcomes for everyone, everywhere."

An Underserved Sector

MindBio recently stated that screening for drug and alcohol intoxication at scale can prevent unnecessary harm through the detection of physiological decline. The company offered statistics that estimate a 10-20x increase in suicide risk while heavily intoxicated. It also claims that 40-50% of suicides involve alcohol, noting that the global alcohol harm cost sits at around US$1.6 trillion.

The risk of addiction and drug or alcohol abuse rises due to many factors, like parental monitoring, peer pressure, socioeconomic status, type of substance, stress, drug availability, and occupation, according to the American Addiction Centers. They cite the mining industry as "particularly conducive to substance abuse," due to job stress, physical demand, and injuries from prolonged work.

The entire biotech sector has shown exponential growth recently. "The global biotechnology market size was estimated at US$1.55 trillion in 2023 and is projected to reach US$3.88 trillion by 2030, growing at a CAGR of 13.96% from 2024 to 2030," said Grandview Research. In September 2025, Market and Market Analysis considered the AI detector market as "undergoing rapid expansion, with estimates projecting a substantial market value surge from approximately US$0.58 billion in 2025 to US$2.06 billion in 2030."

Experts Believe Tech Could Save Millions

On February 3, 2026, The Canadian Mining Journal reported that, "Studies in Chile reveal that alcohol consumption among mining workers exceeds 75%, with over 40% classified as problem drinkers." The article noted the potential efficacy of MindBio's kiosks in accident prevention, saying, "A single preventable incident can cost a mining company hundreds of millions in lost production, union boycotts, and insurance and medical expenses."

Knowlton Thomas, for Techcouver, wrote on January 26, 2026, that ". . . Leveraging more than 50 million data points from drug and alcohol clinical trials and proprietary algorithms across over 100 acoustic parameters, MindBio is now commercializing its technology." 

¹Most recently, Stewart Thomson gave Streetwise Reports a contributed technical analyst opinion about MindBio on April 1, 2026. Thomson rated MindBio as a 'Strong Speculative Buy', with a short-term price target of CA$1.70, a medium-term price target of CA$3.00, and a long-term price target of CA$6.00.

Commercial Trials Planned 

Currently, MindBio is creating inroads into the mining, aviation, construction, and law enforcement industries. 

According to the company's latest presentation, MindBio intends to deploy its Edge AI voice drug and alcohol detection kiosks for the mining and aviation sectors in June 2026, hoping to test at a large scale in zero-tolerance industries. The company is already partnering with mines in South America and is in talks with other industries. 

While enterprise and telehealth capacities are in development right now, future plans include disease prediction and health optimization.

Ownership & Share Information²

MindBio Therapeutics Corp. has a market cap of CA$7.9 million, with 7.28 million shares outstanding.

The company's 52-week trading range is CA$0.50-CA$8.00.

Management and Insiders own approximately 5.80% of MindBio Therapeutics shares, with Retail investors holding the remaining 94.20%.